Paraneoplastic Antibodies

Accreditation Status: UKAS Schedule of Accreditation

2009 Date Scheme started:

Clinical Applicability: Paraneoplastic autoantibodies are seen with a variety of neurological

manifestations and can be associated with an underlying malignancy

ANNA-1 (Hu), ANNA-2 (Ri), PCA-1 (Yo), CRMP5 (CV2), Amphiphysin, **Analytes:**

Ma-2 (Ta) and neurological GAD (SER/038)

The sample analytes included will depend on their prevalence in the general population, therefore not all analytes may be covered during the year

Units for Reporting: Paraneoplastic Antibodies – present or absent

Antibody identification - Analytes from list, ANNA-1 etc

Samples Distributed: Liquid format. Normal and pathological human serum

Number of Distributions per year: 6

Number of Samples per Distribution: 2

Frequency of Distributions: Every two months as outlined in the **Distribution Schedule**

Schedule of Analysis: Data entry is via the web for the submission of results. Data analysis

is commenced 21 days after sample dispatch. Late returns are accepted and will

contribute to the laboratory's cumulative performance statistics

Data Analysis: Qualitative responses are assessed in relation to the designated response

Performance Scoring: MI scoring

Criteria of Performance: Laboratory performance is classified in terms of OMIS derived from

the qualitative responses for all analytes for which the laboratory is registered

over a running analytical window of 6 Distributions (12 months)

The categories of performance are:

Total MIS Good Zero 1-2 Adequate >2

Persistent Poor Performance: Defined as being in the Poor Performance category for two or more

Poor

successive Distributions